Regulatoriskt pressmeddelande25.06.2025 klo 18.00Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Regulatoriskt pressmeddelande25.06.2025 klo 15.00Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market
Regulatoriskt pressmeddelande27.03.2025 klo 17.00Scandion Oncology Announces Results of Annual General Meeting
Regulatoriskt pressmeddelande12.03.2025 klo 14.10Scandion Oncology – Notice convening the Annual General Meeting
Regulatoriskt pressmeddelande26.02.2025 klo 19.40Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks
Regulatoriskt pressmeddelande26.02.2025 klo 19.35Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Regulatoriskt pressmeddelande26.02.2025 klo 19.30Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting
Regulatoriskt pressmeddelande13.01.2025 klo 08.00Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer
Regulatoriskt pressmeddelande20.11.2024 klo 18.30Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Regulatoriskt pressmeddelande14.11.2024 klo 09.30Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Pressmeddelande05.11.2024 klo 18.00Invitation to Scandion Oncology webcast and conference call November 11, 2024
Regulatoriskt pressmeddelande04.11.2024 klo 09.30Scandion Oncology announces the start of the exercise period for warrants of series TO 2
Regulatoriskt pressmeddelande31.10.2024 klo 09.30Correction: Scandion Oncology announces exercise price for warrants of series TO 2
Regulatoriskt pressmeddelande30.10.2024 klo 18.00Scandion Oncology announces exercise price for warrants of series TO 2
Pressmeddelande29.08.2024 klo 13.26Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope